What is the recommended treatment regimen for Mycobacterium other‑than‑tuberculosis (MOTT) infection?

Treatment for MOTT (Mycobacterium Other Than Tuberculosis)

Treatment for MOTT infections must be tailored to the specific species identified, as different organisms require fundamentally different regimens—there is no universal "MOTT treatment." The most critical first step is obtaining species-level identification and appropriate drug susceptibility testing, as treatment efficacy and outcomes depend entirely on which organism is causing disease 1, 2.

Species Identification and Susceptibility Testing

Before initiating therapy, you must:

• Identify the organism to species level using DNA probes (for MAC, M. kansasii, M. gordonae) or HPLC 1
• Perform targeted susceptibility testing based on species:
  • MAC: clarithromycin only 1
  • M. kansasii: rifampin only 1
  • Rapidly growing mycobacteria (M. fortuitum, M. abscessus, M. chelonae): extended panel including amikacin, imipenem, doxycycline, fluoroquinolones, sulfonamides, cefoxitin, clarithromycin, linezolid 1

Treatment by Specific Species

Mycobacterium avium Complex (MAC) - Most Common

For nodular/bronchiectatic disease (most patients):

• Three-times-weekly regimen: Clarithromycin 1,000 mg OR azithromycin 500 mg + rifampin 600 mg + ethambutol 25 mg/kg 1, 2
• This intermittent approach has similar efficacy with better tolerability than daily therapy 2

For fibrocavitary or severe nodular/bronchiectatic disease:

• Daily regimen: Clarithromycin 500-1,000 mg OR azithromycin 250 mg + rifampin 600 mg (or rifabutin 150-300 mg) + ethambutol 15 mg/kg 1, 2
• Add parenteral amikacin or streptomycin three times weekly for initial 2-3 months in severe cases 1, 2

Duration: Treat until culture-negative for 12 months on therapy 1, 2

Critical caveat: Never use a macrolide as monotherapy or with only one companion drug (except in mild nodular/bronchiectatic disease) due to high risk of macrolide resistance 1, 2. Azithromycin-based regimens show better tolerability and lower discontinuation rates than clarithromycin-based regimens 3.

Mycobacterium kansasii - Second Most Common

Standard regimen (rifampin-susceptible):

• Daily: Rifampin 600 mg + ethambutol 15 mg/kg + isoniazid 300 mg + pyridoxine 50 mg 1
• Duration: 12 months of culture-negative sputum 1

For rifampin-resistant M. kansasii:

• Three-drug regimen based on susceptibilities: clarithromycin or azithromycin + moxifloxacin + ethambutol, sulfamethoxazole, or streptomycin 1

This organism is highly susceptible to rifampin, making it one of the more treatable NTM species 4.

Mycobacterium abscessus - Most Difficult

There are no drug regimens of proven or predictable efficacy for M. abscessus 1. This is the most challenging NTM to treat.

Approach:

• Multidrug clarithromycin-based regimen (1,000 mg/day) may cause symptomatic improvement 1
• Surgical resection of localized disease combined with multidrug therapy offers the best chance for cure 1
• Prolonged intravenous therapy with amikacin, tigecycline, or imipenem followed by oral agents 5
• Treatment based on in vitro susceptibilities 1

Rapidly Growing Mycobacteria (M. fortuitum, M. chelonae)

• Treatment based entirely on in vitro susceptibilities 1
• For M. fortuitum pulmonary disease: at least two sensitive drugs including a fluoroquinolone for 12 months of culture-negative sputum 6
• Surgical debridement may be essential for successful therapy in nonpulmonary disease 1

NTM Cervical Lymphadenitis

• Primary treatment: surgical excision with >90% cure rate 1
• Macrolide-based regimen only for extensive disease or poor surgical response 1

Treatment-Refractory Disease

For MAC pulmonary disease failing guideline-based therapy after ≥6 months:

• Add amikacin liposome inhalation suspension (ALIS) to the treatment regimen 2
• This is a strong recommendation based on randomized controlled trial evidence 2
• Assess for acquired macrolide resistance and consider pathogen shifts 7
• Evaluate impact of antibiotics on quality of life before intensification 7

Disseminated MAC Disease (AIDS patients)

Treatment regimen:

• Clarithromycin 1,000 mg/day OR azithromycin 250 mg/day + ethambutol 15 mg/kg/day ± rifabutin 150-350 mg/day 1
• Discontinue when symptoms resolve and immune function reconstitutes 1

Prophylaxis (CD4 <50 cells/μL):

• Azithromycin 1,200 mg/week OR clarithromycin 1,000 mg/day 1

Critical Treatment Principles

1. Never add a single drug to a failing regimen—this creates resistance. Add at least 2-3 new drugs 8
2. Patients respond best to treatment the first time—ensure optimal regimen initially 1
3. Obtain expert consultation for treatment failure, intolerance, or complex cases 1, 2
4. Monitor monthly sputum cultures during therapy to assess response 1
5. Expect clinical improvement within 3-6 months and culture conversion within 12 months on macrolide-containing regimens 1

Common Pitfalls to Avoid

• Starting treatment without species identification and susceptibility testing
• Using macrolide monotherapy or inadequate companion drugs
• Treating M. abscessus with oral therapy alone without considering surgery
• Applying tuberculosis treatment principles to NTM (they are fundamentally different organisms)
• Discontinuing therapy too early before achieving 12 months of culture-negative status
• Exposing surgical wounds or IV catheters to tap water (healthcare-associated NTM prevention) 1